Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jin Medical International (ZJYL) Retained Earnings (2022 - 2025)

Jin Medical International (ZJYL) has disclosed Retained Earnings for 4 consecutive years, with -$923968.0 as the latest value for Q3 2025.

  • Quarterly Retained Earnings fell 66.12% to -$923968.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$923968.0 through Sep 2025, down 66.12% year-over-year, with the annual reading at -$923968.0 for FY2025, 66.12% down from the prior year.
  • Retained Earnings hit -$923968.0 in Q3 2025 for Jin Medical International, down from -$556209.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $16.9 million in Q3 2023 to a low of -$923968.0 in Q3 2025.
  • Historically, Retained Earnings has averaged $7.5 million across 4 years, with a median of $6.9 million in 2022.
  • Biggest five-year swings in Retained Earnings: increased 17.48% in 2023 and later plummeted 103.29% in 2024.
  • Year by year, Retained Earnings stood at $14.4 million in 2022, then grew by 17.48% to $16.9 million in 2023, then crashed by 103.29% to -$556209.0 in 2024, then plummeted by 66.12% to -$923968.0 in 2025.
  • Business Quant data shows Retained Earnings for ZJYL at -$923968.0 in Q3 2025, -$556209.0 in Q3 2024, and $16.9 million in Q3 2023.